RW-93

RW-93 is a drug which acts as a potent and selective sirtuin 2 (SIRT2) inhibitor. It inhibits SIRT2 with an IC₅₀ of 15.5 nM, and is highly selective over SIRT1, SIRT3 and SIRT5, however its activity has not been reported at SIRT4, SIRT6 or SIRT7. It represents a further development of FM358, which resulted from a lead-structure-based hybridization concept derived from SirReal2 and 24a. It was developed to assist with research into the role of SIRT2 in degenerative diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis.^[1][2]

Drug classSirtuin 2 (SIRT2) inhibitor

FormulaC₂₃H₂₂BrN₇O₃S₂

Molar mass588.50 g·mol⁻¹

3D model (JSmol)

• Interactive image

Quick facts Clinical data, Drug class ...

RW-93

Clinical data
Drug class	Sirtuin 2 (SIRT2) inhibitor
Chemical and physical data
Formula	C23H22BrN7O3S2
Molar mass	588.50 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(Nc1ccc(cc1Br)OCc1cnc(s1)NC(=O)CSc1nc(C)cc(C)n1)c1cnn(C)c1
InChI InChI=InChI=1S/C23H22BrN7O3S2/c1-13-6-14(2)28-23(27-13)35-12-20(32)30-22-25-9-17(36-22)11-34-16-4-5-19(18(24)7-16)29-21(33)15-8-26-31(3)10-15/h4-10H,11-12H2,1-3H3,(H,29,33)(H,25,30,32) Key:LTSQUIAHBBIGDD-UHFFFAOYSA-N

Close